E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines

被引:0
|
作者
M Lombaerts
T van Wezel
K Philippo
J W F Dierssen
R M E Zimmerman
J Oosting
R van Eijk
P H Eilers
B van de Water
C J Cornelisse
A-M Cleton-Jansen
机构
[1] Leiden University Medical Center,Department of Pathology
[2] Medical Statistics,Division of Toxicology
[3] Leiden University Medical Center,undefined
[4] Leiden/Amsterdam Center for Drug Research,undefined
[5] Leiden University,undefined
来源
British Journal of Cancer | 2006年 / 94卷
关键词
E-cadherin; epithelial–mesenchymal transition; promoter methylation; mammary cell lines; TFG; pathway;
D O I
暂无
中图分类号
学科分类号
摘要
Using genome-wide expression profiling of a panel of 27 human mammary cell lines with different mechanisms of E-cadherin inactivation, we evaluated the relationship between E-cadherin status and gene expression levels. Expression profiles of cell lines with E-cadherin (CDH1) promoter methylation were significantly different from those with CDH1 expression or, surprisingly, those with CDH1 truncating mutations. Furthermore, we found no significant differentially expressed genes between cell lines with wild-type and mutated CDH1. The expression profile complied with the fibroblastic morphology of the cell lines with promoter methylation, suggestive of epithelial–mesenchymal transition (EMT). All other lines, also the cases with CDH1 mutations, had epithelial features. Three non-tumorigenic mammary cell lines derived from normal breast epithelium also showed CDH1 promoter methylation, a fibroblastic phenotype and expression profile. We suggest that CDH1 promoter methylation, but not mutational inactivation, is part of an entire programme, resulting in EMT and increased invasiveness in breast cancer. The molecular events that are part of this programme can be inferred from the differentially expressed genes and include genes from the TGFβ pathway, transcription factors involved in CDH1 regulation (i.e. ZFHX1B, SNAI2, but not SNAI1, TWIST), annexins, AP1/2 transcription factors and members of the actin and intermediate filament cytoskeleton organisation.
引用
收藏
页码:661 / 671
页数:10
相关论文
共 50 条
  • [1] E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines
    Lombaerts, M
    van Wezel, T
    Philippo, K
    Dierssen, JWF
    Zimmerman, RME
    Oosting, J
    van Eijk, R
    Eilers, PH
    van De Water, B
    Cornelisse, CJ
    Cleton-Jansen, AM
    BRITISH JOURNAL OF CANCER, 2006, 94 (05) : 661 - 671
  • [2] A Pathway for the Control of Anoikis Sensitivity by E-Cadherin and Epithelial-to-Mesenchymal Transition
    Kumar, Sanjeev
    Park, Sun Hee
    Cieply, Benjamin
    Schupp, Jane
    Killiam, Elizabeth
    Zhang, Fan
    Rimm, David L.
    Frisch, Steven M.
    MOLECULAR AND CELLULAR BIOLOGY, 2011, 31 (19) : 4036 - 4051
  • [3] E-cadherin on epithelial–mesenchymal transition in thyroid cancer
    Xiaoyu Zhu
    Xiaoping Wang
    Yifei Gong
    Junlin Deng
    Cancer Cell International, 21
  • [4] E-Cadherin Downregulation is Mediated by Promoter Methylation in Canine Prostate Cancer
    Fonseca-Alves, Carlos Eduardo
    Kobayashi, Priscila Emiko
    Leis-Filho, Antonio Fernando
    Lainetti, Patricia de Faria
    Grieco, Valeria
    Kuasne, Hellen
    Rogatto, Silvia Regina
    Laufer-Amorim, Renee
    FRONTIERS IN GENETICS, 2019, 10
  • [5] Chlamydia trachomatis Infection Is Associated with E-Cadherin Promoter Methylation, Downregulation of E-Cadherin Expression, and Increased Expression of Fibronectin and α-SMA-Implications for Epithelial-Mesenchymal Transition
    Rajic, Jovana
    Inic-Kanada, Aleksandra
    Stein, Elisabeth
    Dinic, Svetlana
    Schuerer, Nadine
    Uskokovic, Aleksandra
    Ghasemian, Ehsan
    Mihailovic, Mirjana
    Vidakovic, Melita
    Grdovic, Nevena
    Barisani-Asenbauer, Talin
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2017, 7
  • [6] Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer
    Hollestelle, Antoinette
    Peeters, Justine K.
    Smid, Marcel
    Timmermans, Mieke
    Verhoog, Leon C.
    Westenend, Pieter J.
    Heine, Anouk A. J.
    Chan, Alan
    Sieuwerts, Anieta M.
    Wiemer, Erik A. C.
    Klijn, Jan G. M.
    van der Spek, Peter J.
    Foekens, John A.
    Schutte, Mieke
    den Bakker, Michael A.
    Martens, John W. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (01) : 47 - 57
  • [7] Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer
    Antoinette Hollestelle
    Justine K. Peeters
    Marcel Smid
    Mieke Timmermans
    Leon C. Verhoog
    Pieter J. Westenend
    Anouk A. J. Heine
    Alan Chan
    Anieta M. Sieuwerts
    Erik A. C. Wiemer
    Jan G. M. Klijn
    Peter J. van der Spek
    John A. Foekens
    Mieke Schutte
    Michael A. den Bakker
    John W. M. Martens
    Breast Cancer Research and Treatment, 2013, 138 : 47 - 57
  • [8] Smoking Induces Epithelial-to-Mesenchymal Transition in Non-Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin
    Nagathihalli, Nagaraj S.
    Massion, Pierre P.
    Gonzalez, Adriana L.
    Lu, Pengcheng
    Datta, Pran K.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (11) : 2362 - 2372
  • [9] Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer
    Zhao, Jun
    Dong, Dahai
    Sun, Lingling
    Zhang, Guiming
    Sun, Lijiang
    INTERNATIONAL BRAZ J UROL, 2014, 40 (02): : 179 - 189
  • [10] Eribulin affects E-cadherin localization consistent with a reversal of the epithelial-to-mesenchymal transition
    Dybdal-Hargreaves, N. F.
    Rohena, C. C.
    Risinger, A. L.
    Mooberry, S. L.
    CANCER RESEARCH, 2016, 76